Feb 3 (Reuters) - Indian drugmaker Mankind Pharma reported a higher third-quarter profit on Tuesday, driven by strong ...

As supply chain vulnerabilities intensify and competition accelerates, the cost of this underutilization could risk India's ...

Analysts said back-to-back trade deals with the U.S. and EU could lift pharma, manufacturing and IT stocks.

With the US accounting for nearly 35% of India’s overall pharma shipments of over $30 billion in FY24-25, the move is ...

The so-called “mother of all deals” lowers import tariffs on European pharma exports from 11% to zero and also eliminates ...

Europe remains a large but under-penetrated destination for Indian drugmakers. Data from the Pharmaceuticals Export Promotion ...

The proposed agreement aims to cut tariffs on medicines and medical devices, potentially lowering healthcare costs, while ...

Jan 23 () - Sun ​Pharmaceutical ‌Industries, India's ‌top drugmaker by ⁠revenue, ‌said on Friday ‍that it has ​received ‌regulatory approval to manufacture and sell ⁠generic ​semaglutide ​in India.

India-based Sun Pharmaceutical Industries Ltd is reportedly evaluating a potential acquisition of Organon & Co (NYSE:OGN), a ...

By Bharath Rajeswaran Feb 1 (Reuters) - Indian benchmarks held on to modest gains in a special trading session on Sunday as ...

Shardul Nautiyal, Mumbai Monday, February 2, 2026, 08:00 Hrs [IST] ...

The European Union (EU) has agreed to offer Indian pharmaceutical and medical devices companies preferential access to EU market, along with cutting tariffs on 97.5 percent of chemical products to ...